

29 September 2008

SELECT VACCINES APPOINTS INTERIM CHIEF EXECUTIVE OFFICER

Select Vaccines Ltd (ASX: SLT) today announced the appointment of Ms Julie Nutting as interim Chief Executive Officer.

Ms Nutting joins Select Vaccines from an unlisted vaccine development company where she held the position of Managing Director. Julie has a strong background in the biotech and pharmaceutical industry, having worked as the CEO of listed biotech company Psiron (now Viralytics) and in senior positions for multinational companies such as Sandoz and Covance. In previous roles she has been responsible for technology acquisition and commercialisation, fund raising, licensing and regulatory affairs to international standards.

Ms Nutting has considerable experience as a director of ASX listed companies and currently serves on the boards of Bio OPS Pty Ltd, Milvella Ltd and the CRC for Asthma and Airways Ltd.

Chairman of Select Vaccines, Mr Robin Beaumont, commented "Recruiting Julie to Select Vaccines is significant for the Company. We believe that Julie's skills and experience will assist in driving the Company through the next stage of development once a thorough review of corporate strategy has been undertaken."

"I am delighted to be leading such an exciting company," said Ms Nutting. "In my view there are multiple opportunities for vaccine development companies. Vaccines represent a fast growing market, which is seeing a renaissance as novel technologies come into the clinic and to market. I am looking forward to leading Select Vaccines through the development and commercialisation of its Anavax™ vaccine candidates."

-ENDS-

About Select Vaccines Limited

Select Vaccines Limited (ASX: SLT) is focused on the development of products targeting infectious diseases of global importance. The Company's Virus-Like Particle (VLP) vaccine technology provides a platform that can deliver a range of vaccine candidates and offers significant potential advantages over existing VLP technologies. Select Vaccines' lead products are an influenza vaccine and a hepatitis C vaccine. Both of these vaccines are in pre-clinical testing. Select Vaccines' principal research activities are undertaken at Melbourne's Burnet Institute, Australia's leading research institute in the field of infectious diseases caused by viruses and other agents.

Further information can be found at www.selectvaccines.com.au

CONTACTS:

Select Vaccines	Media & Investor Relations
Julie Nutting, CEO	Fay Weston – Managing Director, Talk Biotech
T: +61 (0)3 9529 8788	T: +61(0)2 4885 2662 or +61 (0)422 206036
E: info@selectvaccines.com.au	E: fayweston@talkbiotech.com.au